{"commentary":{"count":103,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":44,"podcast":31,"youtube":27,"x_video":1},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05048797\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"NCT05048797","nct_id":"NCT05048797","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct05048797. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":null,"arms":[{"description":"Trastuzumab Deruxtecan (T-DXd)","label":"Arm 1","type":"EXPERIMENTAL"},{"description":"Standard of Care Treatment (platinum, pemetrexed and pembrolizumab)","label":"Arm 2","type":"ACTIVE_COMPARATOR"}],"collaborators":["Daiichi Sankyo"],"completion_date":{"date":"2027-07-30","type":"ESTIMATED"},"conditions":["Locally Advanced or Metastatic Non-Small Cell Lung Cancer"],"enrollment":{"count":454,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Trastuzumab Deruxtecan","type":"DRUG"},{"name":"Cisplatin","type":"DRUG"},{"name":"Carboplatin","type":"DRUG"},{"name":"Pembrolizumab","type":"DRUG"},{"name":"Pemetrexed","type":"DRUG"}],"last_update":"2026-07-10","lead_sponsor":"AstraZeneca","official_title":"An Open-label, Randomized, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Trastuzumab Deruxtecan as First-line Treatment of Unresectable, Locally Advanced, or Metastatic NSCLC Harboring HER2 Exon 19 or 20 Mutations (DESTINY-Lung04)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2026-06-09","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression Free Survival (PFS) by Blinded Independent Central Review (BICR)","timeFrame":"Until progression or death, assessed up to approximately 12 months"}],"references":[],"start_date":{"date":"2021-10-28","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations","url":"https://clinicaltrials.gov/study/NCT05048797"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct05048797"}